{"id":5182,"date":"2025-03-11T17:28:46","date_gmt":"2025-03-11T11:58:46","guid":{"rendered":"https:\/\/trending.niftytrader.in\/?p=5182"},"modified":"2025-05-23T15:37:02","modified_gmt":"2025-05-23T10:07:02","slug":"sun-pharma-shares-gain-over-3-as-brokerages-turn-bullish","status":"publish","type":"post","link":"https:\/\/www.niftytrader.in\/markets\/sun-pharma-shares-gain-over-3-as-brokerages-turn-bullish\/","title":{"rendered":"Sun Pharma Shares Gain Over 3% as Brokerages Turn Bullish on US Biotech Acquisition"},"content":{"rendered":"<h2 data-start=\"93\" data-end=\"161\">Investor Sentiment Positive on Checkpoint Therapeutics Deal<\/h2>\n<p data-start=\"163\" data-end=\"429\">Shares of Sun Pharmaceutical Industries Limited surged over 3% on March 11, 2025, following an upgraded rating by ICICI Securities and continued positive sentiment surrounding its recent acquisition of Nasdaq-listed Checkpoint Therapeutics.<\/p>\n<p data-start=\"431\" data-end=\"758\">The deal, valued at $355 million, marks a significant step in Sun Pharma\u2019s expansion into oncology and immunotherapy, particularly in the PD-L1 inhibitor space. Analysts view this acquisition as a strategic move that strengthens the company\u2019s specialty portfolio, leading to bullish projections for the stock.<\/p>\n<h2 data-start=\"760\" data-end=\"808\">Stock Performance and Brokerage Ratings<\/h2>\n<p data-start=\"810\" data-end=\"1084\">Sun Pharma\u2019s shares traded at \u20b91,655.95 apiece at 1:30 PM IST, reflecting a 2.76% increase from the previous session. The stock has corrected by approximately 10% in the last two months, making it an attractive buy at current levels, according to analysts.<\/p>\n<h3 data-start=\"1086\" data-end=\"1132\">Brokerage Ratings and Target Prices:<\/h3>\n<ul data-start=\"1134\" data-end=\"1557\">\n<li data-start=\"1134\" data-end=\"1300\">ICICI Securities: Upgraded rating from \u2018Hold\u2019 to \u2018Buy\u2019, setting a target price of \u20b91,895 based on 31x FY27 estimated earnings per share (EPS).<\/li>\n<li data-start=\"1301\" data-end=\"1386\">Motilal Oswal: Reiterated \u2018Buy\u2019 rating with a target price of \u20b91,970.<\/li>\n<li data-start=\"1387\" data-end=\"1476\">HDFC Securities: Maintained a \u2018Buy\u2019 stance with a target price of \u20b91,970.<\/li>\n<li data-start=\"1477\" data-end=\"1557\">Incred: Assigned a \u2018Hold\u2019 rating, with a target price of \u20b91,900.<\/li>\n<\/ul>\n<h2 data-start=\"1559\" data-end=\"1632\">Sun Pharma\u2019s $355 Million Acquisition of Checkpoint Therapeutics<\/h2>\n<h3 data-start=\"1634\" data-end=\"1675\">Details of the Acquisition:<\/h3>\n<ul data-start=\"1676\" data-end=\"2015\">\n<li data-start=\"1676\" data-end=\"1794\">Company Acquired: Checkpoint Therapeutics (NASDAQ: CKPT), a US-based oncology-focused biotech company.<\/li>\n<li data-start=\"1795\" data-end=\"1961\">Deal Value: $355 million, including an upfront cash payment of $4.1 per share and an additional $0.7 per share in future milestone-based payments.<\/li>\n<li data-start=\"1962\" data-end=\"2015\">Expected Completion: Second half of 2025.<\/li>\n<\/ul>\n<p data-start=\"2017\" data-end=\"2364\">Checkpoint Therapeutics specializes in PD-L1 inhibitors, which have been highly effective against multiple cancers while causing fewer side effects compared to traditional therapies. This acquisition positions Sun Pharma as a key player in immuno-oncology, reinforcing its commitment to expanding its specialty drug pipeline.<\/p>\n<h2 data-start=\"2366\" data-end=\"2427\">Sun Pharma\u2019s Strategic Expansion in Specialty Pharma<\/h2>\n<p data-start=\"2429\" data-end=\"2586\">Sun Pharma has been actively pursuing strategic acquisitions and collaborations to strengthen its presence in the oncology and immunotherapy space.<\/p>\n<h3 data-start=\"2588\" data-end=\"2641\">Recent Key Acquisitions and Collaborations:<\/h3>\n<ul data-start=\"2643\" data-end=\"2941\">\n<li data-start=\"2643\" data-end=\"2781\">2023: Acquired Concert Pharmaceuticals for $576 million, gaining access to deuterated drug technology for dermatology.<\/li>\n<li data-start=\"2782\" data-end=\"2941\">2024: Entered into a global commercialization, licensing, and supply agreement with Philogen for the specialty immunotherapy drug FIBROMUN.<\/li>\n<\/ul>\n<p data-start=\"2943\" data-end=\"3246\">The acquisition of Checkpoint Therapeutics aligns with Sun Pharma\u2019s long-term growth strategy, which focuses on high-margin specialty drugs rather than traditional generics. Analysts believe that this shift will drive stronger earnings growth and better profit margins in the coming years.<\/p>\n<h2 data-start=\"3248\" data-end=\"3312\">Sun Pharma\u2019s Market Outlook and Future Growth Prospects<\/h2>\n<p data-start=\"3314\" data-end=\"3584\">Sun Pharma has been a leader in the global pharmaceutical industry, particularly in the dermatology, oncology, and ophthalmology segments. With the recent acquisitions and partnerships, the company is poised for continued growth in specialty medicines.<\/p>\n<h3 data-start=\"3586\" data-end=\"3639\">Factors Supporting Sun Pharma\u2019s Growth:<\/h3>\n<ol data-start=\"3641\" data-end=\"4894\">\n<li data-start=\"3641\" data-end=\"3945\">\n<p data-start=\"3644\" data-end=\"3690\">Expansion in Oncology and Immunotherapy:<\/p>\n<ul data-start=\"3694\" data-end=\"3945\">\n<li data-start=\"3694\" data-end=\"3806\">PD-L1 inhibitors provide a significant market opportunity in the global cancer treatment sector.<\/li>\n<li data-start=\"3810\" data-end=\"3945\">The global immuno-oncology market is projected to reach $150 billion by 2030, positioning Sun Pharma as a major player.<\/li>\n<\/ul>\n<\/li>\n<li data-start=\"3947\" data-end=\"4266\">\n<p data-start=\"3950\" data-end=\"4006\">Strong Financial Performance and Growth Potential:<\/p>\n<ul data-start=\"4010\" data-end=\"4266\">\n<li data-start=\"4010\" data-end=\"4136\">Sun Pharma\u2019s focus on specialty drugs has led to higher profitability and reduced reliance on low-margin generics.<\/li>\n<li data-start=\"4140\" data-end=\"4266\">The company continues to invest in research and development (R&amp;D) to drive innovation in oncology and dermatology.<\/li>\n<\/ul>\n<\/li>\n<li data-start=\"4268\" data-end=\"4567\">\n<p data-start=\"4271\" data-end=\"4327\">Positive Market Sentiment &amp; Institutional Backing:<\/p>\n<ul data-start=\"4331\" data-end=\"4567\">\n<li data-start=\"4331\" data-end=\"4459\">Sun Pharma remains a top pick among institutional investors, with major brokerage firms maintaining bullish ratings.<\/li>\n<li data-start=\"4463\" data-end=\"4567\">The stock\u2019s recent correction has created an attractive entry point for long-term investors.<\/li>\n<\/ul>\n<\/li>\n<li data-start=\"4569\" data-end=\"4894\">\n<p data-start=\"4572\" data-end=\"4618\">Regulatory Approvals &amp; Product Launches:<\/p>\n<ul data-start=\"4622\" data-end=\"4894\">\n<li data-start=\"4622\" data-end=\"4751\">Sun Pharma\u2019s pipeline of new specialty drug launches will further enhance its market position and revenue growth.<\/li>\n<li data-start=\"4755\" data-end=\"4894\">Regulatory approvals in the US, Europe, and emerging markets will be key catalysts for the company\u2019s global expansion strategy.<\/li>\n<\/ul>\n<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Investor Sentiment Positive on Checkpoint Therapeutics Deal Shares of Sun Pharmaceutical Industries Limited surged over 3% on March 11, 2025, following an upgraded rating by ICICI Securities and continued positive sentiment surrounding its recent acquisition of Nasdaq-listed Checkpoint Therapeutics. The deal, valued at $355 million, marks a significant step in Sun Pharma\u2019s expansion into oncology [&hellip;]<\/p>\n","protected":false},"author":4,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[615],"tags":[],"ppma_author":[1331],"class_list":{"0":"post-5182","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-stock-market-news"}," _eael_post_view_count":0,"authors":[{"term_id":1331,"user_id":4,"is_guest":0,"slug":"sourabh","display_name":"Sourabh Sharma","avatar_url":{"url":"https:\/\/trending.niftytrader.in\/wp-content\/uploads\/2025\/11\/Sourabh-Sharma.png","url2x":"https:\/\/trending.niftytrader.in\/wp-content\/uploads\/2025\/11\/Sourabh-Sharma.png"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":""}],"_links":{"self":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/5182","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/comments?post=5182"}],"version-history":[{"count":1,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/5182\/revisions"}],"predecessor-version":[{"id":5184,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/posts\/5182\/revisions\/5184"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/media\/5183"}],"wp:attachment":[{"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/media?parent=5182"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/categories?post=5182"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/tags?post=5182"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.niftytrader.in\/markets\/wp-json\/wp\/v2\/ppma_author?post=5182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}